MLTX Quote, Financials, Valuation and Earnings

CRISPR Therapeutics AG has a net margin of -- compared to MoonLake Immunotherapeutics's net margin of -106.6%. MoonLake Immunotherapeutics's return on equity of -- beat CRISPR Therapeutics AG's return on equity of -18.65%.

MoonLake Immunotherapeutics has a consensus price target of $78.31, signalling upside risk potential of 59.81%. On the other hand CRISPR Therapeutics AG has an analysts' consensus of $81.75 which suggests that it could grow by 43.93%. Given that MoonLake Immunotherapeutics has higher upside potential than CRISPR Therapeutics AG, analysts believe MoonLake Immunotherapeutics is more attractive than CRISPR Therapeutics AG.

MoonLake Immunotherapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison CRISPR Therapeutics AG has a beta of 1.822, suggesting its more volatile than the S&P 500 by 82.156%.

MoonLake Immunotherapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CRISPR Therapeutics AG offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. MoonLake Immunotherapeutics pays -- of its earnings as a dividend. CRISPR Therapeutics AG pays out -- of its earnings as a dividend.

MoonLake Immunotherapeutics quarterly revenues are --, which are smaller than CRISPR Therapeutics AG quarterly revenues of $35M. MoonLake Immunotherapeutics's net income of -$39.9M is higher than CRISPR Therapeutics AG's net income of -$136M. Notably, MoonLake Immunotherapeutics's price-to-earnings ratio is -- while CRISPR Therapeutics AG's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MoonLake Immunotherapeutics is -- versus -- for CRISPR Therapeutics AG. Usually stocks with elevated PS ratios are considered overvalued.

Merck & has a net margin of -- compared to MoonLake Immunotherapeutics's net margin of 32.71%. MoonLake Immunotherapeutics's return on equity of -- beat Merck &'s return on equity of 39.02%.

MoonLake Immunotherapeutics has a consensus price target of $78.31, signalling upside risk potential of 59.81%. On the other hand Merck & has an analysts' consensus of $101.79 which suggests that it could grow by 22.11%. Given that MoonLake Immunotherapeutics has higher upside potential than Merck &, analysts believe MoonLake Immunotherapeutics is more attractive than Merck &.

MoonLake Immunotherapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Merck & has a beta of 0.389, suggesting its less volatile than the S&P 500 by 61.063%.

MoonLake Immunotherapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merck & offers a yield of 3.84% to investors and pays a quarterly dividend of $0.81 per share. MoonLake Immunotherapeutics pays -- of its earnings as a dividend. Merck & pays out 45.8% of its earnings as a dividend. Merck &'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

MoonLake Immunotherapeutics quarterly revenues are --, which are smaller than Merck & quarterly revenues of $15.5B. MoonLake Immunotherapeutics's net income of -$39.9M is lower than Merck &'s net income of $5.1B. Notably, MoonLake Immunotherapeutics's price-to-earnings ratio is -- while Merck &'s PE ratio is 12.13x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MoonLake Immunotherapeutics is -- versus 3.31x for Merck &. Usually stocks with elevated PS ratios are considered overvalued.

Novartis AG has a net margin of -- compared to MoonLake Immunotherapeutics's net margin of 26.48%. MoonLake Immunotherapeutics's return on equity of -- beat Novartis AG's return on equity of 30.96%.

MoonLake Immunotherapeutics has a consensus price target of $78.31, signalling upside risk potential of 59.81%. On the other hand Novartis AG has an analysts' consensus of $113.44 which suggests that it could fall by -6.26%. Given that MoonLake Immunotherapeutics has higher upside potential than Novartis AG, analysts believe MoonLake Immunotherapeutics is more attractive than Novartis AG.

MoonLake Immunotherapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Novartis AG has a beta of 0.599, suggesting its less volatile than the S&P 500 by 40.101%.

MoonLake Immunotherapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Novartis AG offers a yield of 3.3% to investors and pays a quarterly dividend of $3.99 per share. MoonLake Immunotherapeutics pays -- of its earnings as a dividend. Novartis AG pays out 63.85% of its earnings as a dividend. Novartis AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

MoonLake Immunotherapeutics quarterly revenues are --, which are smaller than Novartis AG quarterly revenues of $13.6B. MoonLake Immunotherapeutics's net income of -$39.9M is lower than Novartis AG's net income of $3.6B. Notably, MoonLake Immunotherapeutics's price-to-earnings ratio is -- while Novartis AG's PE ratio is 18.94x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MoonLake Immunotherapeutics is -- versus 4.58x for Novartis AG. Usually stocks with elevated PS ratios are considered overvalued.

BeOne Medicines has a net margin of -- compared to MoonLake Immunotherapeutics's net margin of 0.11%. MoonLake Immunotherapeutics's return on equity of -- beat BeOne Medicines's return on equity of -11.54%.

MoonLake Immunotherapeutics has a consensus price target of $78.31, signalling upside risk potential of 59.81%. On the other hand BeOne Medicines has an analysts' consensus of $330.95 which suggests that it could grow by 32.22%. Given that MoonLake Immunotherapeutics has higher upside potential than BeOne Medicines, analysts believe MoonLake Immunotherapeutics is more attractive than BeOne Medicines.

MoonLake Immunotherapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison BeOne Medicines has a beta of 0.282, suggesting its less volatile than the S&P 500 by 71.823%.

MoonLake Immunotherapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BeOne Medicines offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. MoonLake Immunotherapeutics pays -- of its earnings as a dividend. BeOne Medicines pays out -- of its earnings as a dividend.

MoonLake Immunotherapeutics quarterly revenues are --, which are smaller than BeOne Medicines quarterly revenues of $1.1B. MoonLake Immunotherapeutics's net income of -$39.9M is lower than BeOne Medicines's net income of $1.3M. Notably, MoonLake Immunotherapeutics's price-to-earnings ratio is -- while BeOne Medicines's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MoonLake Immunotherapeutics is -- versus 6.43x for BeOne Medicines. Usually stocks with elevated PS ratios are considered overvalued.